Your browser doesn't support javascript.
loading
Differences in prescribed medicinal cannabis use by cannabinoid product composition: Findings from the cannabis as medicine survey 2020 (CAMS-20) Australia-wide study.
Trevitt, Benjamin T; Bailey, Sasha; Mills, Llewellyn; Arkell, Thomas R; Suraev, Anastasia; McGregor, Iain S; Lintzeris, Nicholas.
Afiliación
  • Trevitt BT; Drug and Alcohol Services, South Eastern Sydney Local Health District, Sydney, NSW, Australia.
  • Bailey S; School of Public Health and Community Medicine, UNSW Sydney, Sydney, Australia.
  • Mills L; Faculty of Medicine and Health, The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Camperdown, Australia.
  • Arkell TR; Drug and Alcohol Services, South Eastern Sydney Local Health District, Sydney, NSW, Australia.
  • Suraev A; Speciality Addiction Medicine, Faculty Medicine and Health, University of Sydney, Camperdown, NSW, Australia.
  • McGregor IS; Drug and Alcohol Clinical Research and Improvement Network, St Leonards, NSW, Australia.
  • Lintzeris N; Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, VIC, Australia.
PLoS One ; 19(2): e0297092, 2024.
Article en En | MEDLINE | ID: mdl-38354169
ABSTRACT

INTRODUCTION:

Prescribed medicinal cannabis (MC) is an increasingly common prescription in Australia for treating pain, anxiety, and sleep disorders. Prescribed MC products generally contain tetrahydrocannabinol (THC) and/or cannabidiol (CBD) in a variety of dose levels and forms. It is unclear whether THC and CBD products are used by patients with different characteristics and for different conditions.

OBJECTIVES:

To examine consumer experiences of using THC- and CBD-containing prescribed MC products to better understand how they are being used within the Australian context.

METHODS:

We utilised data collected from an online anonymous cross-sectional survey of individuals (CAMS-20 survey), consisting of Australian residents using cannabis for therapeutic reasons. We focused on a subgroup of participants (N = 546) receiving prescribed MC products. We utilised linear, logistic, and multinomial regression modelling to analyse responses to survey questions based on the cannabinoid profile of the prescribed product.

RESULTS:

Participants prescribed THC-dominant MC products were statistically more likely to be younger, male, and to prefer inhaled routes of administration than participants using CBD-dominant products who were older, female, and preferred oral routes of administration. Pain and mental health were the most common reasons for all types of prescribed MC, but were more likely to be treated with THC than CBD despite the significantly higher risk of mild to severe drowsiness, dry mouth and eye irritation. Consumer reported effectiveness of prescribed MC was very positive, particularly for THC-containing products. Consumers on opioids and antipsychotics were statistically more likely to be prescribed THC-containing products than products containing CBD only, despite the greater risk of impairment.

CONCLUSIONS:

This Australia-wide study found clear differences in consumer-reported experiences of prescribed THC- and CBD-containing products. Current prescriptions of these products do not always align with relevant clinical guidance. Educating prescribers around cannabinoid products is essential to ensure optimal prescribing practices and to prevent avoidable drug side effects and interactions.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cannabidiol / Cannabinoides / Cannabis / Marihuana Medicinal / Alucinógenos Tipo de estudio: Diagnostic_studies / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male País/Región como asunto: Oceania Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cannabidiol / Cannabinoides / Cannabis / Marihuana Medicinal / Alucinógenos Tipo de estudio: Diagnostic_studies / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male País/Región como asunto: Oceania Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos